The earnings call highlighted challenges with revenue decline and specific issues with GeneSight and hereditary cancer testing. However, some positive aspects included growth in prenatal testing and progress in the product pipeline. The company's guidance was revised downwards, indicating significant challenges ahead.

Company Guidance -

Q3 2025

During the Myriad Genetics First Quarter 2025 earnings call, the company updated its 2025 financial guidance due to various challenges, including a decline in GeneSight test volumes and a softer than expected ramp in unaffected hereditary cancer testing. Myriad now projects annual revenue between $807 million and $823 million, down $35 million from the prior midpoint, and adjusted operating expenses between $555 million and $565 million, reduced by $25 million from the prior midpoint. Despite these challenges, Myriad reported strong performance in its prenatal testing, with a revenue growth of 11% year-over-year, and the company plans to launch new products such as the combined carrier screening and NIPS assay, PRECISE MRD, and AI-enabled Prolaris to drive future growth.

Prenatal Testing Growth

Prenatal testing was a highlight in the quarter with revenue growth of 11% year-over-year, and 15% excluding SneakPeak, driven by strong demand for ForeSight and Prequel tests.

Oncology Test Volume Growth

Continued strong demand for the myRisk test for cancer patients, with test volume growth of 11% year-over-year.

Product Pipeline Progress

The company is on track to launch its first gene combined carrier screening and NIPS assay within the next couple of months, and the first AI-enabled Prolaris test by the end of the year.

Gross Margin Improvement

Despite the revenue decline, gross margins expanded by 50 basis points, delivering a 69% gross margin due to lab efficiencies.

Myriad Genetics (MYGN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

MYGN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 04, 2025	2025 (Q3)	>-0.01 / -	0.06	―	―	―
Aug 05, 2025	2025 (Q2)	>-0.01 / 0.05	0.05	0.00% (0.00)
May 06, 2025	2025 (Q1)	-0.06 / -0.03	-0.01	-200.00% (-0.02)
Feb 24, 2025	2024 (Q4)	0.03 / 0.03	0.04	-25.00% (-0.01)
Nov 07, 2024	2024 (Q3)	0.02 / 0.06	-0.03	300.00% (+0.09)
Aug 06, 2024	2024 (Q2)	-0.01 / 0.05	-0.08	162.50% (+0.13)
May 07, 2024	2024 (Q1)	-0.10 / -0.01	-0.21	95.24% (+0.20)
Feb 27, 2024	2023 (Q4)	0.01 / 0.04	-0.12	133.33% (+0.16)
Nov 06, 2023	2023 (Q3)	-0.08 / -0.03	-0.19	84.21% (+0.16)
Aug 03, 2023	2023 (Q2)	-0.08 / -0.08	0.04	-300.00% (-0.12)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

MYGN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$3.87	―	―
May 06, 2025	$7.27	$4.27	-41.27%
Feb 24, 2025	$13.78	$11.74	-14.80%
Nov 07, 2024	$17.67	$17.41	-1.47%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Myriad Genetics (MYGN) report earnings?

Myriad Genetics (MYGN) is schdueled to report earning on Nov 04, 2025, TBA (Confirmed).

What is Myriad Genetics (MYGN) earnings time?

Myriad Genetics (MYGN) earnings time is at Nov 04, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is MYGN EPS forecast?

MYGN EPS forecast for the fiscal quarter 2025 (Q3) is >-0.01.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing